Dupilumab
Dupixent (dupilumab) is a prescription biologic medication that targets underlying inflammation to treat certain chronic conditions. It is used primarily for adults and children with moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis who have not responded adequately to other treatments.
Dupixent is an injectable biologic that reduces inflammation by blocking specific proteins involved in allergic and inflammatory responses, treating conditions like eczema, asthma, and nasal polyps.
Key facts at a glance
- RxNorm
- 1876402
- Generic
- Dupixent
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dupixent is approved to treat moderate-to-severe atopic dermatitis (eczema) in adults and children, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Treatment is typically considered for patients who have not achieved adequate control with topical medications or other standard therapies.
Dupixent is a monoclonal antibody that binds to the alpha subunit of the interleukin-4 receptor, blocking the activity of interleukin-4 (IL-4) and interleukin-13 (IL-13). These signaling proteins play key roles in driving type 2 inflammation, which is involved in the conditions Dupixent treats.
Dupixent is administered as a subcutaneous injection, typically every 2 weeks after an initial loading dose. Common side effects may include injection site reactions, eye redness or irritation, and upper respiratory tract infections. Patients should not use Dupixent to treat acute bronchospasm or breathing emergencies. Regular follow-up with a healthcare provider is important to monitor response and manage any side effects.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy